Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Cancer Trials Ireland
It is proposed that levels of AMH and inhibin A and B measured will give an indication of the residual ovarian reserve in women with breast cancer treated with chemotherapy. In addition, AMH might give an indication of the possible efficacy of GNRH agonists in fertility preservation and the effect on ovarian follicular reserve using different adjuvant chemotherapy regimens. Those likely to be offered GNRH agonists are younger women with no children and a wish to have some in the future. Older women who have completed their families are less likely to be offered a GNRH agonist.
Age
18–50
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
1. Documented histological diagnosis of invasive breast cancer
2. Patient due to be treated with chemotherapy (neoadjuvant or adjuvant)\*
3. Female patients aged between 18 and 50 years
4. Premenopausal status as defined by a hormone profile within the pre-menopausal range as defined by local lab
OR The patient's last menstrual period had to be within the last 180 days
OR An IUD is used for contraception.
5. Ability to provide written informed consent
* Patients treated with GNRH agonist or adjuvant Herceptin or participating in other clinical trials are also eligible
You may not be if
1. Patients with hypothalamic/pituitary disorder
2. History of ovarian tumour
3. Current pregnancy
Clareo Health | Ovarian Reserve in Premenopausal Breast Cancer
